亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

达帕格列嗪 依普利酮 医学 泌尿科 肾脏疾病 内科学 肌酐 蛋白尿 肾功能 交叉研究 盐皮质激素受体 药理学 内分泌学 醛固酮 安慰剂 糖尿病 2型糖尿病 病理 替代医学
作者
Michele Provenzano,María Jesús Puchades,Carlo Garofalo,Niels Jongs,Luis D’Marco,Michele Andreucci,Luca De Nicola,José Luis Górriz,Hiddo J.L. Heerspink
出处
期刊:Journal of The American Society of Nephrology 卷期号:33 (8): 1569-1580 被引量:83
标识
DOI:10.1681/asn.2022020207
摘要

Significance Statement In this randomized crossover clinical trial in patients with CKD with and without type 2 diabetes, we assessed the albuminuria-lowering effect of the sodium glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin and mineralocorticoid receptor antagonist (MRA) eplerenone individually and in combination. We demonstrated that the albuminuria-lowering effects of dapagliflozin and eplerenone alone are additive when they are used in combination, resulting in a clinically relevant albuminuria reduction of 53% after 4 weeks of dapagliflozin-eplerenone treatment. The incidence of hyperkalemia was significantly less with combination treatment compared with eplerenone alone. These data support future clinical trials to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with CKD. We assessed efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD. Methods We conducted a randomized open-label crossover trial in patients with urinary albumin excretion ≥100 mg/24 hr, eGFR 30–90 ml/min per 1.73 m 2 , who had been receiving maximum tolerated stable doses of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-week treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day, or their combination in random order, separated by 4-week washout periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline. Results Of 57 patients screened, 46 were randomly assigned (mean eGFR, 58.1 ml/min per 1.73 m 2 ; median UACR, 401 mg/g) to the three groups. Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was –19.6% (95% confidence interval [CI], –34.3 to –1.5), –33.7% (95% CI, –46.1 to –18.5), and –53% (95% CI, –61.7 to –42.4; P <0.001 versus dapagliflozin; P =0.01 versus eplerenone). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone ( r =–0.13; P =0.47; r =–0.08; P =0.66, respectively). Hyperkalemia was more frequently reported with eplerenone ( n =8; 17.4%) compared with dapagliflozin ( n =0; 0%) or dapagliflozin-eplerenone ( n =2; 4.3%; P between-groups =0.003). Conclusions Albuminuria changes in response to dapagliflozin and eplerenone did not correlate, supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR-lowering effect. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. Clinical Trial registry name and registration number: European Union Clinical Trials Register, EU 2017–004641–25.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JLHN完成签到,获得积分10
45秒前
科目三三次郎完成签到 ,获得积分10
1分钟前
Puan完成签到,获得积分10
2分钟前
5分钟前
zsmj23完成签到 ,获得积分0
5分钟前
zhaozhao完成签到 ,获得积分10
7分钟前
冷傲渊思完成签到,获得积分10
7分钟前
谢小盟完成签到 ,获得积分10
7分钟前
7分钟前
上官若男应助安之若素采纳,获得10
7分钟前
Perry完成签到,获得积分10
7分钟前
咕咕咕咕发布了新的文献求助30
8分钟前
咕咕咕咕完成签到,获得积分10
8分钟前
安之若素完成签到,获得积分20
8分钟前
8分钟前
安之若素发布了新的文献求助10
8分钟前
10分钟前
gszy1975发布了新的文献求助10
10分钟前
大喜子完成签到 ,获得积分10
12分钟前
科研通AI2S应助欣喜若灵采纳,获得10
12分钟前
12分钟前
欣喜若灵发布了新的文献求助10
12分钟前
赘婿应助krajicek采纳,获得30
13分钟前
13分钟前
Mayer1234088发布了新的文献求助10
13分钟前
14分钟前
krajicek发布了新的文献求助30
14分钟前
14分钟前
liufinity发布了新的文献求助10
15分钟前
柿饼完成签到,获得积分10
15分钟前
英俊的铭应助liufinity采纳,获得10
15分钟前
15分钟前
krajicek发布了新的文献求助10
15分钟前
大个应助科研通管家采纳,获得10
15分钟前
小马甲应助科研通管家采纳,获得30
15分钟前
雪糕考研完成签到 ,获得积分10
15分钟前
16分钟前
liufinity发布了新的文献求助10
16分钟前
沧海云完成签到 ,获得积分10
16分钟前
Akim应助EmmaZ采纳,获得10
18分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154982
求助须知:如何正确求助?哪些是违规求助? 2805698
关于积分的说明 7865848
捐赠科研通 2463950
什么是DOI,文献DOI怎么找? 1311678
科研通“疑难数据库(出版商)”最低求助积分说明 629728
版权声明 601853